The CBX5 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human cell line, designed to introduce loss-of-function disruption of the CBX5 gene. CBX5 encodes HP1??, a critical component of heterochromatin organization and epigenetic gene silencing. This polyclonal product consists of a heterogeneous pool of edited cells, offering a population-level representation of CBX5 deficiency without clonal selection. The knockout model enables broad functional interrogation of CBX5-dependent chromatin regulation and its consequences on genome stability and transcriptional control.
The host cell line SK-HEP-1 is a human liver sinusoidal endothelial cell line originally isolated from the ascites of a patient with liver adenocarcinoma. As a hepatic endothelial model, SK-HEP-1 retains properties relevant to liver cancer biology, making it particularly suitable for studying hepatocellular carcinoma and associated vascular interactions. Its tumor origin provides a context for investigating epigenetic mechanisms that drive oncogenic processes within the liver microenvironment. This cell line is widely used in research on tumor?Cendothelial crosstalk, drug penetration, and metastasis.
CBX5 (HP1??) functions as a reader of H3K9me3 histone marks, binding to di- and trimethylated lysine 9 on histone H3. Through its chromodomain, HP1?? localizes to heterochromatic regions and recruits protein complexes to maintain chromatin compaction and transcriptional silencing. It interacts with SUV39H1, SETDB1, Lamin B receptor, MeCP2, CAF-1, and DNMT1. Upstream regulators include the histone methyltransferases SUV39H1 and SETDB1, Aurora B kinase, HDACs, and p53. CBX5 mediates silencing of repetitive elements, tumor suppressor genes, lineage-specific genes, and E2F target genes. The H3K9me3?CCBX5?CSETDB1 axis is central to heterochromatin assembly and propagation. Knockout of CBX5 disrupts this network, leading to loss of H3K9me3 enrichment at target loci, chromatin decondensation, and derepression of silenced genomic regions.
In the SK-HEP-1 background, loss of CBX5 function likely compromises epigenetic barriers that restrain oncogenic programs, offering a powerful model to study hepatocellular carcinoma progression. The interplay between hepatic endothelial identity and cancer origin means that CBX5-dependent gene silencing may regulate pathways involved in cell adhesion, migration, and tumor suppressor reactivation. This knockout population can be used to explore how heterochromatin disruption contributes to genomic instability and altered gene expression profiles characteristic of liver malignancies. It also serves as a platform for dissecting chromatinopathies and developmental disorders linked to CBX5 dysfunction.
The CBX5 Knockout SK-HEP-1 Polyclonal Cells support a variety of experimental applications, including the study of epigenetic regulation, cancer epigenetics, chromatin biology, drug screening, and metastasis modeling. Representative assays include ChIP-qPCR for H3K9me3, immunofluorescence staining of HP1?? foci, RT-qPCR to quantify expression of derepressed genes, Western blotting for HP1??, RNA-seq, invasion assays, and colony formation assays. These cells enable detailed mechanistic studies and therapeutic target validation in a physiologically relevant endothelial?Ccancer model. For further information, please contact Ascent Research.
